Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREATE: Crizotinib in ALK/MET-driven tumors
NCT01524926Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of crizotinib in anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumor (IMT), papillary renal cell carcinoma type 1, alveolar soft part sarcoma (ASPS), clear cell sarcoma (CCS), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2012; status: completed.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory myofibroblastic tumor (IMT)papillary renal cell carcinoma type 1alveolar soft part sarcoma (ASPS)clear cell sarcoma (CCS)
Beyond the preview
Go deeper on NCT01524926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524926.